Strand | GenomeWeb


The two companies, who announced the merger in January, said they could not complete the terms of their deal in a timely enough manner.

The Strand Center for Genomics and Personalized Medicine lab is now accredited in India to perform three of Strand's most popular tests. 

Once the deal is fully concluded, Strand's shareholders will own approximately 68 percent of the new company, while Venaxis shareholders will own 32 percent.

Strand provides a standard of care report that includes a handful of genes and IHC markers within eight days, and the full 152-gene report seven to 12 days later.

The companies anticipate launching the next-generation sequencing-based tests in Russia "in the near future."

Under the terms of the agreement, Tataa will distribute and support Strand's analysis software in Europe and will also use the tool in training programs.

The StrandAdvantage test currently analyzes 48 cancer-related genes on one of the laboratory's three Illumina MiSeq instruments.

The partners will integrate Strand's informatics software with MRI Global's mobile diagnostic labs and co-develop companion diagnostics.

NEW YORK (GenomeWeb) – Bangalore, India-based Leucine Rich Bio has developed and is preparing to launch a new cloud-based software-as-a-service solution dubbed CtoG to help clinical genetics laboratories identify potentially harmful mutations in data from their next-generation sequencing-based te

Strand Life Sciences said this week that Scott Storrer has joined its staff as president of its North American business.


In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.